JILIN AODONG(SZ:000623)2023-11-01 02:54Company Overview - Jilin Aodong Pharmaceutical Group Co., Ltd. operates under a multi-wheel drive model of "Pharmaceuticals + Finance + Health" and adheres to the business philosophy of "World Health, Aodong Responsibility" [2] - As of September 30, 2023, the company reported total assets of CNY 32.168 billion, an increase of 3.19% from the beginning of the year [2] - The net assets attributable to shareholders reached CNY 10.02 billion, growing by 3.85% [2] Financial Performance - The company's net profit for the first three quarters of 2023 was CNY 1.274 billion, a year-on-year increase of 44.72% [2] - The asset-liability ratio stood at 15.01% [2] - The company has maintained a continuous profit for several years, with a net profit exceeding CNY 1 billion [2] Business Segments Pharmaceutical Sector - The pharmaceutical business includes traditional Chinese medicine, chemical drugs, and retail pharmacy operations [3] - In the first three quarters, the company achieved sales revenue from 2 products exceeding CNY 100 million and 24 products exceeding CNY 10 million [3] - The sales growth rate for the "Nerve and Heart Comfort Oral Liquid" reached 146.69% year-on-year [3] Health Sector - The health segment produced over 200 types of health functional foods and dietary supplements in 2023, with 22 health food registration certificates and 76 filing certificates [3] - Five products in this segment achieved sales revenue exceeding CNY 10 million, with over 30 products exceeding CNY 1 million [3] Financial Investment - The financial investment segment includes a significant stake in GF Securities, with the company holding 1,252,297,867 A-shares and 213,702,600 H-shares, totaling 19.7199% of GF Securities' total share capital [3] - The company has conducted multiple share buybacks, investing CNY 570 million to repurchase 36,158,251 shares [4] Strategic Initiatives - The company has completed the listing of 368 varieties of traditional Chinese medicine formula granules, enhancing its market competitiveness [5] - A project for traditional Chinese medicine formula granules is expected to generate annual sales revenue of CNY 1.262635 billion and an average annual profit of CNY 234.9227 million [5]